Mitsubishi Tanabe Articles

Top-line financial results from Japanese drug majors

9 May 2013

Amyotrophic lateral sclerosis sector lacks new and effective treatment options

6 February 2013

Takeda, Shionogi, Ono Pharma and Mitsubishi Tanabe post nine-month results

4 February 2013

Dezima Pharma in-licenses CETP inhibitor; Imaxio acquires Trolovol

22 January 2013

FDA panel backs J&J diabetes drug Invokana (canagliflozin)

11 January 2013

First interferon-free regimens for hepatitis C virus expected to launch in 2014 in the USA and Europe

20 December 2012

Covagen collaborates with Mitsubishi Tanabe for the development of bispecific FynomAbs

17 October 2012

Mitsubishi Tanabe to take full control of Bipha JV

3 September 2012

AnGes deal with Mitsubishi Tanabe Pharma for Collategene in USA

4 July 2012

Janssen files NDA with FDA for canagliflozin in type 2 diabetes

1 June 2012

Synageva expands collaboration with Mitsubishi Tanabe Pharma

3 April 2012

Medicago in vaccine development alliance with Mitsubishi Tanabe

8 March 2012

Disappointing first-half FY 2011/12 results from Japanese drugmakers

31 October 2011

Astellas in-licenses antibody from Evec; Mitsubishi Tanabe deal with Synageva

6 September 2011

Tanabe in $115 million R&D deal with Anaphore for novel protein drugs for autoimmune disorders

14 December 2010

Novartis/Mitsubishi Tanabe's Gilenia remains on track for blockbuster sales in the multiple sclerosis drug market

16 June 2010

Showing 1-16 of 16 articles

Go to beginningPrevious
  • 1
NextGo to end